Individual risk evaluation for local recurrence and distant metastasis in Ewing sarcoma: A multistate model A multistate model for Ewing sarcoma

被引:19
|
作者
Bosma, S. E. [1 ]
Rueten-Budde, A. J. [2 ]
Lancia, C. [2 ]
Ranft, A. [3 ,4 ]
Dirksen, U. [3 ,4 ]
Krol, A. D. [5 ]
Gelderblom, H. [6 ]
van de Sande, M. A. J. [1 ]
Dijkstra, P. D. S. [1 ]
Fiocco, M. [2 ,7 ]
机构
[1] Leiden Univ, Med Ctr, Dept Orthoped, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands
[2] Leiden Univ, Math Inst, Leiden, Netherlands
[3] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Sarcoma Ctr,German Canc Consortium,Pediat 3, Essen, Germany
[4] German Canc Consortium DKTK, Essen, Germany
[5] Leiden Univ, Med Ctr, Dept Radiotherapy, Leiden, Netherlands
[6] Leiden Univ, Med Ctr, Dept Med Oncol, Leiden, Netherlands
[7] Leiden Univ, Med Ctr, Med Stat Biomed Data Sci, Leiden, Netherlands
基金
欧盟第七框架计划;
关键词
Ewing sarcoma; multistate model; personalized medicine; prediction; survival; PROGNOSTIC-FACTORS; CHEMOTHERAPY; TUMORS; BONE; EXPERIENCE; SURVIVAL; ADJUVANT; SURGERY; THERAPY; PROGRAM;
D O I
10.1002/pbc.27943
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background We investigated the effects of surgical margins, histological response, and radiotherapy on local recurrence (LR), distant metastasis (DM), and survival in Ewing sarcoma. Procedure Disease evolution was retrospectively studied in 982 patients with Ewing sarcoma undergoing surgery after chemotherapy using a multistate model with initial state surgery, intermediate states LR, pulmonary metastasis (DMpulm), other DM +/- LR (DMother), and final state death. Effect of risk factors was estimated using Cox proportional hazard models. Results The median follow-up was 7.6 years (95% CI, 7.2-8.0). Risk factors for LR are pelvic location, HR 2.04 (1.10-3.80), marginal/intralesional resection, HR 2.28 (1.25-4.16), and radiotherapy, HR 0.52 (0.28-0.95); for DMpulm the risk factors are <90% necrosis, HR 2.13 (1.13-4.00), and previous pulmonary metastasis, HR 4.90 (2.28-8.52); for DMother are 90% to 99% necrosis, HR 1.56 (1.09-2.23), <90% necrosis, HR 2.66 (1.87-3.79), previous bone/other metastasis, HR 3.08 (2.03-4.70); and risk factors for death without LR/DM are pulmonary metastasis, HR 8.08 (4.01-16.29), bone/other metastasis, HR 10.23 (4.90-21.36), and <90% necrosis, HR 6.35 (3.18-12.69). Early LR (0-24 months) negatively influences survival, HR 3.79 (1.34-10.76). Once DMpulm/DMother arise only previous bone/other metastasis remain prognostic for death, HR 1.74 (1.10-2.75). Conclusion Disease extent and histological response are risk factors for progression to DM or death. Tumor site and surgical margins are risk factors for LR. If disease progression occurs, previous risk factors lose their relevance. In case of isolated LR, time to recurrence is important for decision-making. Radiotherapy seems protective for LR especially in pelvic/axial. Low percentages of LR in extremity tumors and associated toxicity question the need for radiotherapy in extremity Ewing sarcoma.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Evaluation of polymorphisms in EWSR1 and risk of Ewing sarcoma: A report from the childhood cancer survivor study
    DuBois, Steven G.
    Goldsby, Robert
    Segal, Mark
    Woo, Jonathan
    Copren, Kirsten
    Kane, John P.
    Pullinger, Clive R.
    Matthay, Katherine K.
    Witte, John
    Lessnick, Stephen L.
    Robison, Leslie L.
    Bhatia, Smita
    Strong, Louise C.
    PEDIATRIC BLOOD & CANCER, 2012, 59 (01) : 52 - 56
  • [42] A logical model of Ewing sarcoma cell epithelial-to-mesenchymal transition supports the existence of hybrid cellular phenotypes
    Silveira, Daner A.
    Gupta, Shantanu
    Jaeger, Mariane da Cunha
    de Farias, Caroline Brunetto
    Mombach, Jose Carlos Merino
    Sinigaglia, Marialva
    FEBS LETTERS, 2023, 597 (19) : 2446 - 2460
  • [43] Radiomics model for predicting distant metastasis in soft tissue sarcoma of the extremities and trunk treated with surgery
    Yang, Miaomiao
    Jin, Jiyang
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, : 2307 - 2315
  • [44] High neuropeptide Y release associates with Ewing sarcoma bone dissemination - in vivo model of site-specific metastases
    Hong, Sung-Hyeok
    Tilan, Jason U.
    Galli, Susana
    Izycka-Swieszewska, Ewa
    Polk, Taylor
    Horton, Meredith
    Mahajan, Akanksha
    Christian, David
    Jenkins, Shari
    Acree, Rachel
    Connors, Katherine
    Ledo, Phuong
    Lu, Congyi
    Lee, Yi-Chien
    Rodriguez, Olga
    Toretsky, Jeffrey A.
    Albanese, Chris
    Kitlinska, Joanna B.
    ONCOTARGET, 2015, 6 (09) : 7151 - 7165
  • [45] Factors Influencing Long-Term Local Recurrence, Distant Metastasis, and Survival in Patients with Soft Tissue Sarcoma of the Extremities Treated with Radiotherapy
    Lebas, Arthur
    Le Fevre, Clara
    Waissi, Waisse
    Chambrelant, Isabelle
    Brinkert, David
    Noel, Georges
    CANCERS, 2024, 16 (10)
  • [46] Development of a Preclinical Orthotopic Xenograft Model of Ewing Sarcoma and Other Human Malignant Bone Disease Using Advanced In Vivo Imaging
    Vormoor, Britta
    Knizia, Henrike K.
    Batey, Michael A.
    Almeida, Gilberto S.
    Wilson, Ian
    Dildey, Petra
    Sharma, Abhishek
    Blair, Helen
    Hide, I. Geoff
    Heidenreich, Olaf
    Vormoor, Josef
    Maxwell, Ross J.
    Bacon, Chris M.
    PLOS ONE, 2014, 9 (01):
  • [47] TCR-transgenic T cells and YB-1-based oncolytic virotherapy improve survival in a preclinical Ewing sarcoma xenograft mouse model
    Schober, Sebastian J.
    Thiede, Melanie
    Gassmann, Hendrik
    von Ofen, Anna Josefine
    Knoch, Pia
    Eck, Jennifer
    Prexler, Carolin
    Kordass-Wally, Corazon
    Hauer, Julia
    Burdach, Stefan
    Holm, Per Sonne
    Thiel, Uwe
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [48] Regorafenib regressed a doxorubicin-resistant Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude mouse model
    Miyake, Kentaro
    Kiyuna, Tasuku
    Kawaguchi, Kei
    Higuchi, Takashi
    Oshiro, Hiromichi
    Zhang, Zhiying
    Wangsiricharoen, Sintawat
    Razmjooei, Sahar
    Li, Yunfeng
    Nelson, Scott D.
    Murakami, Takashi
    Hiroshima, Yukihiko
    Matsuyama, Ryusei
    Bouvet, Michael
    Chawla, Sant P.
    Singh, Shree Ram
    Endo, Itaru
    Hoffman, Robert M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (05) : 809 - 815
  • [49] Equivocal end-of-therapy imaging findings do not predict a higher risk of local relapse after definitive radiotherapy in pediatric Ewing sarcoma and rhabdomyosarcoma
    McLean-Thomas, Lorna
    Gao, Dexiang
    Trenbeath, Zachary
    Cost, Carrye R.
    Milgrom, Sarah A.
    PEDIATRIC BLOOD & CANCER, 2023, 70 (05)
  • [50] Effect of radiotherapy on local recurrence, distant metastasis and overall survival in 1200 extremity soft tissue sarcoma patients. Retrospective analysis using IPTW-adjusted models
    Smolle, Maria A.
    Andreou, Dimosthenis
    Woelfel, Judith
    Acem, Ibtissam
    Van De Sande, Michiel Aj
    Jeys, Lee
    Bonenkamp, Han
    Pollock, Rob
    Tunn, Per-Ulf
    Haas, Rick
    Posch, Florian
    Van Ginkel, Robert J.
    Verhoef, Cornelis
    Liegl-Atzwanger, Bernadette
    Moustafa-Hubmer, Dalia
    Jost, Philipp J.
    Leithner, Andreas
    Szkandera, Joanna
    RADIOTHERAPY AND ONCOLOGY, 2023, 189